News

24/10/14
Stallergenes continues its international expansion with the opening of an affiliate in Canada.

STALLERGENES S.A. (Euronext Paris), a global healthcare company...

[more]
23/10/14
Stallergenes sales reach €45.7 million in Q3 2014; Oralair® achieves market leadership in France; Continued expansion of international markets (up 33%)

Antony, France; 23 October 2014 – 6.00pm CET

 

Q3 2014 sales...

[more]

Follow us on :

STALLERGENES, A GLOBAL ALLERGY PLAYER


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. 

Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.